Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136265

Published: 2020

Journal Articles

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria

Blood (2020) 135 (12): 912–920.

https://doi.org/10.1182/blood.2019003399

Published: 2020

Includes: Supplemental data

Journal Articles

Exposure-Response Relationship of the SMART-Ig Anti-hC5 Antibody Crovalimab (SKY59): Results from the Umbrella Phase 1/2 Composer Trial in Healthy Volunteers and PNH Patients

Alexandre Sostelly, M.Eng., PhD, Simon Buatois, Antoine Soubret, Erica Winter, PharmD, Barbara Klughammer, PhD, Joy C. Hsu, Gregor Jordan, Christoph Bucher, MD, Jean-Eric Charoin, Keisuke Gotanda, Kenji Shinomiya, Zsolt Nagy, MD PhD, Jens P. Panse, Sung-Soo Yoon, MD PhD, Régis Peffault de Latour, MD PhD, Junichi Nishimura, MD PhD, Alexander Röth, MD PhD

Blood (2019) 134 (Supplement_1): 3745.

https://doi.org/10.1182/blood-2019-124258

Published: 2019

Journal Articles

Characterizing C5 Inhibition with the SMART-Ig Anti-hC5 Antibody Crovalimab in PNH Patients Using Free Available Paratopes

Alexandre Sostelly, M.Eng., PhD, Antoine Soubret, Christoph Bucher, MD, Simon Buatois, Jean-Eric Charoin, Gregor Jordan, Barbara Klughammer, PhD, Andreas Dieckmann, Taku Fukuzawa, PhD, Keisuke Gotanda, Kenji Shinomiya, Sung-Soo Yoon, MD PhD, Jens P. Panse, Junichi Nishimura, MD PhD, Alexander Röth, MD PhD, Zsolt Nagy, MD PhD, Régis Peffault de Latour, MD PhD

Blood (2019) 134 (Supplement_1): 1227.

https://doi.org/10.1182/blood-2019-126911

Published: 2019

Journal Articles

The SMART Anti-hC5 Antibody (SKY59/RO7112689) Shows Good Safety and Efficacy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Blood (2018) 132 (Supplement 1): 535.

https://doi.org/10.1182/blood-2018-99-113274

Published: 2018

Journal Articles

Evaluation Of The Pre-Transplantation Workup Before Allogeneic Transplantation and Reasons For Delaying Or Cancelling Transplant

Sabine Gerull, MD, Andreas S Buser, MD, Christoph Bucher, MD, Dominik Heim, MD, Michael Medinger, MD, Jakob Passweg, MD, Martin Stern, MD

Blood (2013) 122 (21): 5456.

https://doi.org/10.1182/blood.V122.21.5456.5456

Published: 2013

Journal Articles

Intra-Arterial Catheter Guided Steroid Administration For The Treatment Of Steroid-Refractory Intestinal GvHD

Michael Medinger, MD, David Buergler, MD, Jakob Passweg, MD, Arne Fischmann, MD, Christoph Bucher, MD

Blood (2013) 122 (21): 4604.

https://doi.org/10.1182/blood.V122.21.4604.4604

Published: 2013

Journal Articles

Fully Automated Washing of Cryopreserved Peripheral Blood Stem Cells (PBSC): Results of a Prospective, Multicenter, Clinical Trial.

Riccardo Saccardi, MD, Miguel Blanquer, MD, Margherita Boieri, Christoph Bucher, MD, Christian Chabannon, MD, PhD, Simone Dal Pozzo, Benjamin Esterni, Ph.D., Francesco Lanza, MD, Claude Lemarie, Maria Dolores Lopez Lucas, Doris Loutan, Jose M Morelada Jimenez, Andre Tichelli, MD, Boris Calmels

Blood (2012) 120 (21): 3164.

https://doi.org/10.1182/blood.V120.21.3164.3164

Published: 2012

Journal Articles

Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes

Keli L. Hippen, Christoph Bucher, Dawn K. Schirm, Amanda M. Bearl, Ty Brender, Kathy A. Mink, Kimberly S. Waggie, Regis Peffault de Latour, Anne Janin, Julie M. Curtsinger, Stacey R. Dillon, Jeffrey S. Miller, Gerard Socie, Bruce R. Blazar

Blood (2012) 119 (2): 619–628.

https://doi.org/10.1182/blood-2011-07-368027

Published: 2012

Includes: Supplemental data

Journal Articles

Constitutively active Stat5b in CD4 + T cells inhibits graft-versus-host disease lethality associated with increased regulatory T-cell potency and decreased T effector cell responses

Christine Vogtenhuber, Christoph Bucher, Steven L. Highfill, Lisa K. Koch, Emily Goren, Angela Panoskaltsis-Mortari, Patricia A. Taylor, Michael A. Farrar, Bruce R. Blazar

Blood (2010) 116 (3): 466–474.

https://doi.org/10.1182/blood-2009-11-252825

Published: 2010

Includes: Supplemental data

Journal Articles

Birth order and outcome after HLA–identical sibling donor transplantation

Alois Gratwohl, Bernd Doehler, Martin Stern, Christoph Bucher, Jakob Passweg, Gerhard Opelz

Blood (2009) 114 (27): 5569–5570.

https://doi.org/10.1182/blood-2009-10-249060

Published: 2009

Journal Articles

IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation

Christoph Bucher, Lisa Koch, Christine Vogtenhuber, Emily Goren, Meghan Munger, Angela Panoskaltsis-Mortari, Pallavur Sivakumar, Bruce R. Blazar

Blood (2009) 114 (26): 5375–5384.

https://doi.org/10.1182/blood-2009-05-221135

Published: 2009

Includes: Supplemental data

Journal Articles

Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality

Lisa K. Jasperson, Christoph Bucher, Angela Panoskaltsis-Mortari, Andrew L. Mellor, David H. Munn, Bruce R. Blazar

Blood (2009) 114 (24): 5062–5070.

https://doi.org/10.1182/blood-2009-06-227587

Published: 2009

Includes: Supplemental data

Journal Articles

High-Dose Melphalan Re-Induction with or without Stem Cell Support Prior to Myeloablative Allogeneic Stem Cell Transplantation in Patients with Advanced Relapsed or Refractory Acute Myeloid Leukemia.

Alix O'Meara, MD, Thomas Pabst, MD, Dominik Heim, MD, Christoph Bucher, MD, Joerg Halter, MD, Caroline Arber, MD, Alicia Rovò, André Tichelli, MD, Alois Gratwohl, MD, Martin Stern, MD

Blood (2009) 114 (22): 2271.

https://doi.org/10.1182/blood.V114.22.2271.2271

Published: 2009

Journal Articles

Cyclophosphamide-Busulfan Instead of Busulfan-Cyclophosphamide for Conditioning in Allogeneic Hematopoietic Stem Cell Transplantation.

Nathan Cantoni, Sabine Gerull, Dominik Heim, Joerg Halter, Dimitrios Tsakiris, Christoph Bucher, Alicia Rovo, Caroline Arber, Andreas S. Buser, Jakob R. Passweg, Andre Tichelli, Martin Stern, Alois Gratwohl

Blood (2009) 114 (22): 2268.

https://doi.org/10.1182/blood.V114.22.2268.2268

Published: 2009

Journal Articles

Cyclosporine Levels and Rate of Graft Rejection Following Reduced Intensity Conditioning.

Sabine Gerull, MD, Joerg Halter, Christoph Bucher, Dominik Heim, MD, André Tichelli, MD, Alois Gratwohl, MD, Martin Stern, MD

Blood (2009) 114 (22): 3337.

https://doi.org/10.1182/blood.V114.22.3337.3337

Published: 2009

Journal Articles

Inducing the Tryptophan Catabolic Pathway, Indoleamine 2,3-Dioxygenase (IDO), for Suppression of Graft-Versus-Host Disease (GVHD) Lethality.

Lisa Jasperson, Christoph Bucher, MD, Angela Panoskaltsis-Mortari, PhD, Andrew Mellor, David H. Munn, MD, Bruce R. Blazar, MD

Blood (2009) 114 (22): 3547.

https://doi.org/10.1182/blood.V114.22.3547.3547

Published: 2009

Journal Articles

The Bidirectional Relationship Between Cytomegalovirus Replication and Graft-Versus-Host Disease - a Retrospective Single Center Study.

Nathan Cantoni, Hans H Hirsch, Nina Khanna, Dominik Heim, Joerg Halter, Dimitrios Tsakiris, Christoph Bucher, Alicia Rovò, Caroline Arber, MD, Andreas S Buser, Andre Tichelli, Alois Gratwohl, Martin Stern

Blood (2009) 114 (22): 2236.

https://doi.org/10.1182/blood.V114.22.2236.2236

Published: 2009

Journal Articles

Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia

Qing Zhou, Christoph Bucher, Meghan E. Munger, Steven L. Highfill, Jakub Tolar, David H. Munn, Bruce L. Levine, Megan Riddle, Carl H. June, Daniel A. Vallera, Brenda J. Weigel, Bruce R. Blazar

Blood (2009) 114 (18): 3793–3802.

https://doi.org/10.1182/blood-2009-03-208181

Published: 2009

Includes: Supplemental data

Journal Articles

Treg Depletion with Interleukin-2-Diphteriatoxin (IL-2DT) Is Sufficient to Induce Tumor Clearance in Acute Myeloid Leukemia (AML)

Christoph Bucher, MD, Johanna Zhou, PhD, Heidi Mondale, PhD, Meghan Johnson, Luna Liu, Christine Vogtenhuber, PhD, Chris Lees, Yoichiro Iwakura, PhD, Daniel A Vallera, PhD, Brenda Weigel, MD, MSc, Bruce R. Blazar, MD

Blood (2008) 112 (11): 2954.

https://doi.org/10.1182/blood.V112.11.2954.2954

Published: 2008

NARROW

An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria

Exposure-Response Relationship of the SMART-Ig Anti-hC5 Antibody Crovalimab (SKY59): Results from the Umbrella Phase 1/2 Composer Trial in Healthy Volunteers and PNH Patients

Characterizing C5 Inhibition with the SMART-Ig Anti-hC5 Antibody Crovalimab in PNH Patients Using Free Available Paratopes

The SMART Anti-hC5 Antibody (SKY59/RO7112689) Shows Good Safety and Efficacy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Evaluation Of The Pre-Transplantation Workup Before Allogeneic Transplantation and Reasons For Delaying Or Cancelling Transplant

Intra-Arterial Catheter Guided Steroid Administration For The Treatment Of Steroid-Refractory Intestinal GvHD

Fully Automated Washing of Cryopreserved Peripheral Blood Stem Cells (PBSC): Results of a Prospective, Multicenter, Clinical Trial.

Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes

Constitutively active Stat5b in CD4 + T cells inhibits graft-versus-host disease lethality associated with increased regulatory T-cell potency and decreased T effector cell responses

Birth order and outcome after HLA–identical sibling donor transplantation

IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation

Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality

High-Dose Melphalan Re-Induction with or without Stem Cell Support Prior to Myeloablative Allogeneic Stem Cell Transplantation in Patients with Advanced Relapsed or Refractory Acute Myeloid Leukemia.

Cyclophosphamide-Busulfan Instead of Busulfan-Cyclophosphamide for Conditioning in Allogeneic Hematopoietic Stem Cell Transplantation.

Cyclosporine Levels and Rate of Graft Rejection Following Reduced Intensity Conditioning.

Inducing the Tryptophan Catabolic Pathway, Indoleamine 2,3-Dioxygenase (IDO), for Suppression of Graft-Versus-Host Disease (GVHD) Lethality.

The Bidirectional Relationship Between Cytomegalovirus Replication and Graft-Versus-Host Disease - a Retrospective Single Center Study.

Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia

Treg Depletion with Interleukin-2-Diphteriatoxin (IL-2DT) Is Sufficient to Induce Tumor Clearance in Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only